GI Cognition Gut Health Test Review: Essential for GLP-1 Users?

GLP-1 receptor agonists profoundly change how the gut functions. Gastric emptying slows. Intestinal transit time increases. Appetite signalling from the gut-brain axis shifts. For most users, these changes are the mechanism of benefit — the satiety, the reduced cravings, the weight loss.

But the same changes that make GLP-1 medications effective can disrupt gut microbial ecology, worsen pre-existing gut symptoms, or create new ones. Constipation affects up to 24% of semaglutide users. Nausea and vomiting affect over 40%. And beneath the obvious symptoms, many users experience changes they struggle to attribute clearly to GLP-1 versus underlying gut dysfunction.

GI Cognition is a UK-based gut health testing company offering microbiome analysis, digestive function panels, and gut inflammation markers. The question is whether their testing adds meaningful clinical value for GLP-1 users — and what you'd actually do with the results.

How GLP-1 Changes the Gut

Before evaluating any test, it's worth understanding what GLP-1 therapy does to the gut environment:

Gastric emptying. GLP-1 receptor agonists slow gastric emptying — the rate at which the stomach releases food into the small intestine. This is one of the primary satiety mechanisms. In STEP 1 trial data, semaglutide users showed significantly delayed gastric emptying at 20 weeks. The clinical consequence: food stays in the stomach longer, which contributes to nausea and early fullness, but also means slower delivery of substrates to the intestinal microbiome.

Intestinal transit time. Reduced food intake and slowed motility both increase colonic transit time. This is the mechanistic basis for GLP-1-associated constipation. Slow transit changes the fermentation environment — bacteria have longer to process substrates, which can alter short-chain fatty acid (SCFA) production and microbial composition.

Appetite peptides. GLP-1 receptors are expressed throughout the gut. GLP-1 agonists interact with endogenous gut hormone signalling in ways that extend beyond simple appetite suppression — affecting CCK, PYY, and ghrelin, all of which influence gut function.

Microbiome shifts. Emerging research suggests that GLP-1 therapy directly modifies gut microbiome composition, and that the microbiome may in turn modulate GLP-1 efficacy. The relationship is bidirectional.

What GI Cognition Tests

GI Cognition offers several testing panels, with the core product being a comprehensive gut microbiome and digestive function analysis using a home-collected stool sample.

The standard panel includes:

Microbiome diversity analysis. Bacterial diversity at genus and species level, compared against a reference population. Diversity is a marker of gut ecosystem health — lower diversity is consistently associated with metabolic disease, inflammation, and reduced SCFA production.

Keystone species identification. Specific bacteria with outsized influence on gut function: Akkermansia muciniphila (gut barrier integrity), Faecalibacterium prausnitzii (anti-inflammatory), Bifidobacterium species (immune modulation), and Lactobacillus strains.

Short-chain fatty acid markers. SCFAs — particularly butyrate, propionate, and acetate — are produced by bacterial fermentation of dietary fibre. Butyrate is the primary fuel for colonocytes and has significant anti-inflammatory effects. Reduced SCFA production is a feature of dysbiosis.

Inflammatory markers. Calprotectin (a marker of intestinal inflammation — elevated in inflammatory bowel disease and significant dysbiosis) and potentially zonulin (gut permeability marker).

Digestive function markers. Pancreatic elastase (exocrine pancreatic function), bile acid metabolism indicators, and other functional markers that reveal how well digestion is proceeding rather than just what bacteria are present.

The test is conducted at home — a stool collection kit is posted to you, and the sample is returned by mail. Results are typically available within 2-3 weeks with an online report and recommendations.

Why GLP-1 Users Are a Relevant Testing Population

Most people who buy microbiome tests are healthy individuals who are curious. For GLP-1 users, the value proposition is different because:

You are actively changing your gut environment. GLP-1 therapy is one of the most significant gut interventions people will experience outside of antibiotics or surgery. Understanding your baseline microbiome before or early in treatment gives you a reference point. Testing 3-6 months into treatment reveals what's actually changing.

Constipation is often dysbiosis-amplified. GLP-1-induced constipation has a direct motility cause, but its severity varies enormously between users. Part of that variation is the pre-existing microbial community. Users with low butyrate-producing bacteria or low Faecalibacterium prausnitzii abundance tend to have worse constipation. A test that identifies this directs a more specific intervention (targeted probiotic or prebiotic) rather than generic fibre advice.

Nausea persistence may be partly microbiome-mediated. There's emerging evidence that gut dysbiosis can amplify nausea signals via the gut-brain axis. Not every persistent nausea case on GLP-1 is medication dose-related — some reflects a gut environment that was already dysfunctional before the GLP-1 was started. See the GLP-1 side effects guide for the full symptom picture.

Probiotic selection becomes evidence-based rather than guesswork. The UK supplement market sells dozens of probiotic products with largely overlapping strain lists. Knowing your actual microbiome composition transforms probiotic selection from a stab in the dark to a targeted intervention. See probiotics on Ozempic for the specific strain guidance.

Interpreting Your Results: What Matters

Gut microbiome reports can be overwhelming. For GLP-1 users, these are the markers worth prioritising:

Butyrate-producing bacteria. Look for Faecalibacterium prausnitzii, Roseburia intestinalis, and Butyricicoccus pullicaecorum. Low abundance here explains constipation, poor gut barrier function, and suboptimal SCFA production. The intervention is targeted prebiotic fibre (inulin, FOS, pectin) and in some cases direct butyrate supplementation.

Akkermansia muciniphila. This species is genuinely important — it colonises the mucus layer and maintains gut barrier integrity. Low Akkermansia is associated with increased gut permeability ("leaky gut"), metabolic disease, and poorer responses to dietary intervention. Interestingly, the Dahl 2024 data showed semaglutide increased Akkermansia abundance, which may partly explain GLP-1's metabolic benefits beyond weight loss.

Diversity index. A low Shannon diversity index (or equivalent metric) indicates a less resilient gut ecosystem. High-diversity microbiomes are associated with better metabolic outcomes, lower inflammation, and better responses to both dietary and medication interventions.

Calprotectin. Calprotectin above 50 mcg/g warrants attention and GP discussion. It indicates active intestinal inflammation that should be investigated independently of GLP-1 therapy. Don't assume elevated calprotectin is GLP-1-related — it could be IBD, infection, or other pathology.

Pancreatic elastase. Low elastase indicates exocrine pancreatic insufficiency — a condition that causes fat malabsorption, loose stools, and nutritional deficiency. This is unrelated to GLP-1 but clinically important if present. GLP-1 affects the endocrine pancreas (insulin secretion) but not exocrine function.

What You Can Do With the Results

Testing without actionable follow-through is just expensive curiosity. Here is how GI Cognition results translate into specific interventions:

Low butyrate producers:

• Add resistant starch to diet: cooled cooked potato, green banana, oats
• Consider psyllium husk (5-10g daily) — a well-tolerated prebiotic on GLP-1
• Targeted probiotic strains: Lactobacillus reuteri, Faecalibacterium prausnitzii (if available)

Low Akkermansia:

• Polyphenol-rich foods: pomegranate, cranberry, grape seed extract
• Prebiotic inulin — Akkermansia is an inulin-responsive species
• Time-restricted eating patterns are associated with Akkermansia abundance increases

Low diversity:

• Increase dietary fibre variety (different fibre types feed different species)
• Fermented foods: kefir, live yoghurt, kimchi, sauerkraut
• A broad-spectrum probiotic with 10+ strains as a foundation

Elevated calprotectin:

• Discuss with GP regardless of GLP-1 status — this requires clinical evaluation
• Do not self-treat with probiotics and assume it will resolve

Poor pancreatic function:

• GP referral for formal investigation
• Enzyme replacement therapy (Creon) if confirmed pancreatic exocrine insufficiency

For broader monitoring alongside gut health, the GLP-1 monitoring protocol covers the full blood and biomarker picture.

Timing: When to Test

Before starting GLP-1: Establishes your baseline. Useful if you have pre-existing gut symptoms (IBS, constipation, bloating) that might be exacerbated by GLP-1.

3-6 months into treatment: The microbiome changes induced by GLP-1 and dietary shifts are established by this point. Testing here reveals whether the changes are moving in a beneficial direction and identifies what still needs addressing.

When symptoms persist: If constipation, nausea, bloating, or other GI symptoms are not resolving after the standard adaptation period (typically 8-12 weeks), gut testing provides a more specific diagnostic framework than general side effect management advice.

After antibiotic use: Antibiotics disrupt the microbiome significantly. If you've taken a course during GLP-1 treatment, a follow-up test 6-8 weeks later gives a useful picture of recovery.

Limitations and Honest Assessment

Gut microbiome testing has real limitations worth understanding before purchase:

Population reference ranges are imperfect. The "optimal" microbiome is not fully defined. Reference ranges are based on healthy populations, but what constitutes healthy varies by diet, geography, and genetics. A result flagged as low-diversity relative to the reference population may be normal for your diet and ancestry.

Snapshot in time. The microbiome changes day-to-day based on what you eat, your stress levels, and your activity. A single test captures one moment. Repeat testing 3-6 months apart gives a more meaningful picture than a single snapshot.

The test identifies targets; clinical validation requires a GP. Elevated calprotectin, low pancreatic elastase, or very high diversity loss should prompt GP discussion, not self-treatment. GI Cognition's value is in directing you toward specific interventions and identifying red flags — not replacing clinical evaluation.

---

Always consult your GP if gut symptoms persist or worsen on GLP-1 therapy. Elevated calprotectin or significant change in bowel habit warrants clinical evaluation regardless of GLP-1 treatment status.